Summary
On 27 March 2020, Medicines Australia (MA) lodged an application for authorisation on behalf of itself and its members, and the Generic and Biosimilar Medicines Association (GBMA) and its members (together the MA/GBMA Working Group) and any future members of the MA/GBMA Working Group. MA initially sought authorisation for six months to implement a coordinated strategy in relation to the supply of essential medicines and related supplies in response to the current COVID-19 pandemic. MA also sought urgent interim authorisation, in light of the current demands on the health system and in order to assist relevant government bodies.
On 3 April 2020, the ACCC granted interim authorisation with certain conditions.
On 26 June 2020, the ACCC issued a draft determination proposing to grant authorisation with certain conditions until 27 March 2021. In its submission on the draft determination, MA requested authorisation for 12 months.
On 24 September 2020, the ACCC issued a final determination granting authorisation to MA with certain conditions until 30 September 2021. A copy of the final determination is available below.
A timetable is set out below for your information
|
Indicative date |
Stage in assessment process |
|
27 March 2020 |
Lodgement of application, including request for interim authorisation |
|
3 April 2020 |
ACCC decision on interim authorisation |
|
6 April 2020 |
Public consultation |
|
27 April 2020 |
Closing date for submissions |
|
18 May 2020 |
Applicant responds to issues raised in public consultation process |
|
26 June 2020 |
ACCC draft determination |
|
July/August 2020 |
Public consultation on the draft determination |
|
24 September 2020 |
ACCC final determination |
Authorisation number(s)
- AA1000486-1